BMJ  2005;330:1442-1443 (18 June), doi:10.1136/bmj.330.7505.1442

Education and debate

For and against

Aspirin for everyone older than 50?

AGAINST

¹ Clinical Trial Service Unit and Epidemiological Studies Unit, Radcliffe Infirmary, Oxford OX2 6HE colin.baigent@ctsu.ox.ac.uk

Current population screening for vascular disease is neither efficient nor effective. Peter Elwood and colleagues believe we should have a public information strategy highlighting the benefits (and risks) of aspirin for older people, but Colin Baigent argues that the evidence of benefit is not yet strong enough

The first 150 words of the full text of this article appear below.

Introduction

An age threshold approach to aspirin prophylaxis in people without known vascular disease has two important problems. The balance of benefits and risks of aspirin in people aged 70 or over has not been clearly defined in randomised trials, and the benefits do not clearly exceed the risks in younger people without vascular disease. Consequently, it would be unwise to adopt such a policy, whatever age threshold is chosen, until we are sure that older patients will derive net benefit from it.

What studies show

Among high risk patients with known occlusive arterial disease and a greater than 3% annual risk of a vascular event (defined as non-fatal myocardial infarction, non-fatal stroke, or vascular death), the benefits of aspirin substantially outweigh the risks of bleeding. A recent meta-analysis of randomised trials of antiplatelet drugs versus control showed that for every 1000 such patients treated for a year, aspirin would be expected to prevent . . . [Full text of this article]

Risk of vascular events and bleeding

CiteULike    Complore    Connotea    Del.icio.us    Digg    Reddit    Technorati    What's this?

Relevant Articles

Aspirin for everyone over 50?: Don't forget aspirin resistance

Ketan K Dhatariya
BMJ 2005 331: 161. [Extract] [Full Text]

Should everyone over 50 take aspirin prophylaxis?
BMJ 2005 330: 0. [Full Text]

Make up your own minds

Fiona Godlee
BMJ 2005 330: 0. [Extract] [Full Text] [PDF]

Aspirin for everyone older than 50?: FOR

Peter Elwood, Gareth Morgan, Ginevra Brown, and Janet Pickering
BMJ 2005 330: 1440-1441. [Extract] [Full Text] [PDF]

Collaborative meta-analysis of randomised trials of antiplatelet therapy for prevention of death, myocardial infarction, and stroke in high risk patients

Antithrombotic Trialists' Collaboration
BMJ 2002 324: 71-86. [Abstract] [Full Text] [PDF]

This article has been cited by other articles:

• Elwood, P., Morgan, G. (2008). Aspirin for all over 50 revisited. Heart 94: 1364-1365 [Full text]  
• Jankowski, J., Hunt, R. (2008). Cyclooxygenase-2 Inhibitors in Colorectal Cancer Prevention: Counterpoint. Cancer Epidemiol. Biomarkers Prev. 17: 1858-1861 [Abstract] [Full text]  
• Patrono, C., Garcia Rodriguez, L. A., Landolfi, R., Baigent, C. (2005). Low-dose aspirin for the prevention of atherothrombosis.. NEJM 353: 2373-2383 [Full text]  
• Dhatariya, K. K (2005). Aspirin for everyone over 50?: Don't forget aspirin resistance. BMJ 331: 161-161 [Full text]  

Online poll

Find out more >>